img

Get In Touch

img

NIFTY 10192.95 img -47.20

SENSEX 33053.04 img -174.95

GOLD 28411.00

SILVER 36398.00

1 USD / INR 64.44

Attention Investors! "Prevent Unauthorised Transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of Investors."           Attention Investors! "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from NSDL/CDSL on the same day. Issued in the interest of investors."           "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."           "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."           "As per SEBI guidelines, old DIS cannot be accepted for execution of instruction with effect from 07-01-2016. Kindly submit requisition slip / letter for issuance of new DIS booklet at our corporate office address to avoid rejection of your instruction(s) on or after 07-01-2016.”            "In accordance with the Union Budget 2017-18 announcement, SEBI has advised to link Aadhar with individual demat accounts. Kindly submit details of Aadhar number along with copy of Aadhar Card.”          

Market News

  • 10

    Oct
    2017

    Biocon gains after US drug regulator issues CRL to biosimilar

    The announcement was made before market hours today, 10 October 2017.

    Meanwhile, the S&P BSE Sensex was up 101.65 points or 0.32% at 31,948.54.

    On the BSE, 3.66 lakh shares were traded on the counter so far as against the average daily volumes of 4.47 lakh shares in the past one quarter. The stock had hit a high of Rs 361 and a low of Rs 347 so far during the day. The stock had hit a record high of Rs 424.15 on 19 July 2017 and a 52-week low of Rs 267.83 on 9 November 2016.

    The stock had underperformed the market over the past one month till 9 October 2017, advancing 0.42% compared with the Sensex`s 0.5% rise. The stock had, however, outperformed the market over the past one quarter, advancing 2.02% as against the Sensex`s 1.55% rise. The scrip had underperformed the market over the past one year, gaining 9.28% as against the Sensex`s 13.49% rise.

    The large-cap company has equity capital of Rs 300 crore. Face value per share is Rs 5.

    The US Food and Drug Administration (USFDA) has issued a complete response letter (CRL) for Mylan`s Biologics License Application (BLA) for MYL-1401H, a proposed biosimilar pegfilgrastim. This product is a part of the biosimilars portfolio being developed jointly by Biocon and Mylan.

    The CRL relates to the pending update of the BLA with certain CMC data from facility requalification activities post recent plant modifications. The CRL did not raise any questions on biosimilarity, pharmacokinetic/pharmacodynamic data, clinical data or immunogenicity.

    Biocon does not expect this CRL to impact the commercial launch timing of biosimilar pegfilgrastim in the US. Biocon said it is committed to working with the agency to resolve the issues stated in the CRL expeditiously.

    On a consolidated basis, net profit of Biocon declined 51.2% to Rs 81.30 crore on 5.6% decline in net sales to Rs 927.40 crore in Q1 June 2017 over Q1 June 2016.

    Biocon is India`s largest and fully-integrated, innovation-led biopharmaceutical company.

    Powered by Capital Market - Live News